drugset / Trial / NCT01623713

Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

NCT01623713

Phase 2 Completed 260 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether iloperidone is effective in the treatment of Schizophrenia.

Timeline

Start
2012-06
Primary completion
2013-10
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule
Comparator Risperidone Other / unclassified

Indications